TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00509782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101
Description: Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
Study: NCT00917709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging with IBVM
Description: in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol

Intervention type: OTHER
Group type: OTHER
Intervention: Imaging with IBVM
Description: in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imaging with IBVM
Description: in vivo molecular imaging of presynaptic molecular target of cholinergic systems with \[123I\]-iodobenzovesamicol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging with DATSCAN
Description: in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN

Intervention type: OTHER
Group type: OTHER
Intervention: Imaging with DATSCAN
Description: in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
Study: NCT00086489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: pts treated at 10 mg/kg dose level on a monthly regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: pts treated at 15 mg/kg dose level on a quarterly regimen
Study: NCT02424890

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MDT simulation sessions of management of life-threatening events over 1 year
Description: 9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MDT simulation sessions of management of life-threatening events over 1 year
Description: 9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
Study: NCT02359500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET
Description: 68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
Study: NCT01404884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SUPRACOR
Description: The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
Study: NCT03524664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning In to kids intervention
Description: The Tuning Into Kids Program involves:~* Meeting in a small group with other caregivers raising children with FASD.~* 8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~* Learn and practice an approach of responding to children's emotions and behavior.
Study: NCT03481933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial stimulation
Description: 1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial stimulation
Description: 1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial stimulation
Description: 1. 10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~   * left-excitatory tDCS (N=20)~  * right-inhibitory tDCS (N=20)~  * sham tDCS (N=20)~2. 4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~3. 2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS
Study: NCT01288742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: One 10-mg tablet for 1 day (Trt C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: One 150-mg capsule once daily for 7 days (Trts B and D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: One 0.25-mg tablet for 1 day (Trt A)
Study: NCT04865016

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)
Description: This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis +2.75 D (ZKB00) and Tecnis Symfony (ZXR00)
Description: This study included 30 eyes of 15 cataract patients undergoing cataract surgery with implantation of a low add (+2.75 Diopters \[D\]) bifocal (Tecnis ZKB00; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (MIOL Group) and 30 eyes of 15 patients with implantation of an EDOF (Tecnis Symfony \[ZXR00\]; Johnson and Johnson Surgical Vision Inc., Jacksonville, Florida, USA) IOL (EDOF Group).
Study: NCT02495714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active learning
Description: Physical activity one hour a day as part of academic learning
Study: NCT00917709

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Imaging with DATSCAN
Description: in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation using neuropsychological tests

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation using neuropsychological tests

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation using neuropsychological tests
Study: NCT02914652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
Study: NCT01013779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions
Study: NCT01839656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study: NCT01295684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
Study: NCT03705975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual treatment
Description: Scapula mobilization, glenohumeral joint mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual treatment
Description: Scapula mobilization, glenohumeral joint mobilization
Study: NCT01713556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Trauma reactivation
Description: Trauma reactivation: script-driven mental imagery of the traumatic event

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma reactivation
Description: Trauma reactivation: script-driven mental imagery of the traumatic event

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03300297

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Spine Thrust Joint Manipulation
Description: High velocity, short amplitude thrust to the cervical spine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cervical Spine Sham Manipulation
Description: Manipulative hold position shy of end range without a thrust
Study: NCT02914652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norflouran (Placebo Evohaler(R) )
Description: Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norflouran (Placebo Evohaler(R) )
Description: Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norflouran (Placebo Evohaler(R) )
Description: Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
Study: NCT04407312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol Tablets
Description: Cilostazol-SR, capsule, 200mg, once daily, 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo, tablet, 200mg, once daily, 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Astrix, capsule,100mg, once daily, 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Astrix, capsule,100mg, once daily, 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Plavix, tablet, 75mg, once daily, 30 days.
Study: NCT03300297

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home Program
Description: therapeutic exercise program and education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Program
Description: therapeutic exercise program and education

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Suboccipital Release
Description: suboccipital soft tissue mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital Release
Description: suboccipital soft tissue mobilization
Study: NCT04407312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Plavix, tablet, 75mg, once daily, 30 days.
Study: NCT04120974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal insulin injection
Description: subjects receive training in optimal injection technique.
Study: NCT00881933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyclophosphosphamide, TBI
Description: fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, \& -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, \& -8) total body irradiation (3G on days -1)
Study: NCT03089606

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG PET/CT scan
Description: 18F-fluorodeoxy glucose (FDG) positron emission tomography (PET) with intravenous (IV) contrast images are obtained before and at the end study treatment (pembrolizumab infusion).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: C11-AMT PET scan
Description: 11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) images are obtained before study treatment (pembrolizumab infusion).

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan
Description: Computerized tomography (CT) images are taken without IV contrast before the treatment (pembrolizumab infusion) and with IV contrast 3 months after the treatment start.
Study: NCT01482247

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: Dietary Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Dietary Supplement
Study: NCT01980355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06473259

Intervention type: DRUG
Intervention: Docetaxel
Description: 6 courses of docetaxel 75 mg/sqm iv

Intervention type: DRUG
Intervention: Docetaxel
Description: 6 courses of docetaxel 75 mg/sqm iv

Intervention type: DRUG
Intervention: Apalutamide Oral Tablet
Description: 240 mg /daily orally

Intervention type: DRUG
Intervention: Enzalutamide Oral Tablet
Description: 600 mg /daily orally

Intervention type: DRUG
Intervention: Abiraterone acetate tablets
Description: 1000 mg /daily orally
Study: NCT02495714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary councelling
Description: Teaching children and parents about a healthy diet
Study: NCT06473259

Intervention type: DRUG
Intervention: Darolutamide Oral Tablet
Description: 600 mg/daily orally

Intervention type: RADIATION
Intervention: radiotherapy
Description: radical radiotherapy on primary tumor

Intervention type: DRUG
Intervention: Triptorelin
Description: 3,75 mg im/4 w

Intervention type: DRUG
Intervention: Triptorelin
Description: 3,75 mg im/4 w

Intervention type: DRUG
Intervention: Triptorelin
Description: 3,75 mg im/4 w

Intervention type: DRUG
Intervention: Triptorelin
Description: 3,75 mg im/4 w
Study: NCT04087252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor neoantigen
Description: tumor neoantigens
Study: NCT01534949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 by intravenous \[IV\] infusion
Study: NCT04100304

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: resection
Description: CT volumetry,liver function,biopsy before resection
Study: NCT00478985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imatinib ending
Description: Interruption of the treatment by Imatinib
Study: NCT02401594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
Study: NCT03984591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone according to guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone according to guidelines
Study: NCT00495755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath)
Description: An escalating dose given over 4 weeks
Study: NCT02430324

Intervention type: OTHER
Intervention: posttraumatic cerebral infarction
Description: the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
Study: NCT02723669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR10
Description: effervescent tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylcysteine
Description: oral solution
Study: NCT05513495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The effect of drip versus intermittent feeding on splanchnic oxygenation
Description: After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The effect of drip versus intermittent feeding on splanchnic oxygenation
Description: After preterm delivery the infants were randomly assigned to one of two feeding modalities: drip (3-hour continuous) or intermittent (bolus in 10 minutes).
Study: NCT02436551

Intervention type: OTHER
Intervention: Observation
Study: NCT01425957

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Description: All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36).
Study: NCT02558712

Intervention type: OTHER
Group type: OTHER
Intervention: Technology-based Eye Care Services (TECS) Protocol
Description: Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
Study: NCT01351844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and exercise intervention
Description: An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education and General Exercise
Description: A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
Study: NCT04343599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Description: The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
Study: NCT00271609

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
Study: NCT05058300

Intervention type: DEVICE
Intervention: CT Thorax
Description: CT Thorax (GE Revolution with chest pain algorithm)
Study: NCT01410045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovariectomy
Description: Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
Study: NCT01547000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release guanfacine (Intuniv)
Description: 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
Study: NCT02312778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA Manipulation
Description: Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
Study: NCT04438460

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood test
Description: For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: For patient group, blood tests will be performed at day 1-2, day 3-5 and day 60.~For control group, blood test will be performed the day of elective surgery.
Study: NCT00569088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbs formula
Description: The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
Study: NCT03604640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Physical exercise program and health education